Publications by authors named "Nafis Hasan"

Vitamin D3 (vitD3) has been implicated in various cellular functions affecting multiple tissue types. Epidemiological and laboratory studies suggest that vitD3 may be effective as a preventive or therapeutic option for breast cancer. However, randomized clinical trials have yet to confirm these suggestions.

View Article and Find Full Text PDF

Chemotherapy is a mainstay of treatment for solid tumors. However, little is known about how therapy-induced immune cell infiltration may affect therapy response. We found substantial CD45 immune cell density adjacent to E-selectin expressing inflamed vessels in doxorubicin (DOX)-treated residual human breast tumors.

View Article and Find Full Text PDF

Vitamin D3 (vitD3) and its active metabolite, calcitriol (1,25-(OH)D), affect multiple tissue types by interacting with the vitamin D receptor (VDR). Although vitD3 deficiency has been correlated with increased incidence of breast cancer and less favorable outcomes, randomized clinical trials have yet to provide conclusive evidence on the efficacy of vitD3 in preventing or treating breast cancer. Additionally, experimental studies are needed to assess the biological plausibility of these outcomes.

View Article and Find Full Text PDF

Tumor-associated macrophages (TAMs) are major constituents of the tumor microenvironment in solid tumors and have been implicated as mediators of tumor progression, invasion and metastasis. Correspondingly, accumulation of TAMs is associated with unfavorable clinical outcomes in numerous types of solid tumors. E-selectin is a hallmark of inflammation and a key adhesion molecule that accommodates the initial contact of circulating immune cells with the inflamed vessel surface.

View Article and Find Full Text PDF
Article Synopsis
  • E-selectin is an adhesion molecule on inflamed blood vessels that helps tumor cells stick to these vessels, aiding metastasis, and an E-selectin antagonistic thioaptamer (ESTA) was developed to block this adhesion in breast cancer cells.
  • The study aimed to enhance ESTA's pharmaceutical properties by creating a PEGylated version called ESTA7, which effectively inhibits the interaction between E-selectin and CD44 breast cancer cells, similar to the original ESTA.
  • The 10 kDa PEG-conjugated ESTA7 (ESTA7-p10) not only maintained anti-metastatic activity but also showed improved pharmacokinetics, allowing for a longer-lasting effect and tolerating multiple doses in mice, suggesting its
View Article and Find Full Text PDF
Article Synopsis
  • Distant metastasis from breast cancer contributes significantly to mortality, with E-selectin on endothelial cells facilitating cancer cell movement through its interaction with CD44.
  • The study examined how soluble E-selectin (sE-selectin) affects the adhesion and migration of breast cancer cells and leukocytes, finding it specifically promoted these processes in CD44(+) cancer cell lines.
  • sE-selectin increased adhesion and migration through pathways involving CD44 and FAK, as well as enhanced infiltration of cancer cells into tissues, indicating sE-selectin's role in tumor progression and metastasis.
View Article and Find Full Text PDF

Shear-resistant adhesion and extravasation of disseminated cancer cells at the target organ is a crucial step in hematogenous metastasis. We found that the vascular adhesion molecule E-selectin preferentially promoted the shear-resistant adhesion and transendothelial migration of the estrogen receptor (ER)(-)/CD44(+) hormone-independent breast cancer cells, but not of the ER(+)/CD44(-/low) hormone-dependent breast cancer cells. Coincidentally, CD44(+) breast cancer cells were abundant in metastatic lung and brain lesions in ER(-) breast cancer, suggesting that E-selectin supports hematogenous metastasis of ER(-)/CD44(+) breast cancer.

View Article and Find Full Text PDF

Background: High risk, unfavorable classical Hodgkin lymphoma (cHL) includes those patients with primary refractory or early relapse, and progressive disease. To improve the availability of biomarkers for this group of patients, we investigated both tumor biopsies and peripheral blood leukocytes (PBL) of untreated (chemo-naïve, CN) Nodular Sclerosis Classic Hodgkin Lymphoma (NS-cHL) patients for consistent biomarkers that can predict the outcome prior to frontline treatment.

Methods And Materials: Bioinformatics data mining was used to generate 151 candidate biomarkers, which were screened against a library of 10 HL cell lines.

View Article and Find Full Text PDF

RNA interference (RNAi) is a powerful approach for silencing oncogenes; however, in vivo RNAi delivery has remained a major challenge due to lack of safe, efficient, and sustained delivery. Here, we describe a novel approach to overcome these limitations using mesoporous silicon particles loaded with nanoparticles (i.e.

View Article and Find Full Text PDF